Kymera Therapeutics (KYMR) is back in focus after announcing that Phase 1b data for its oral STAT6 degrader KT-621 will appear in a late-breaking oral session at the 2026 American Academy of Dermatology meeting.

At a share price of US$77.91, Kymera’s 1 year total shareholder return of 139.43% and 3 year total shareholder return of 165.63% point to strong momentum, even with a 10.86% 1 month share price decline and recent profit taking by investors such as Nextech ahead of the anticipated KT-621 data spotlight at AAD 2026.

If this kind of clinical catalyst interests you, it can be useful to see what else is moving in related areas via 36 healthcare AI stocks

With Kymera posting triple digit multi year returns, a US$6.36b market cap and a value score of 2, the key question now is whether KT-621 excitement leaves upside on the table or if markets are already pricing in future growth.

Most Popular Narrative: 34.9% Undervalued

With Kymera closing at $77.91 against a most followed fair value estimate of $119.71, the prevailing narrative sees meaningful upside grounded in its type 2 disease and oral degrader pipeline.

With a significant cash runway extending into mid-2027, Kymera can support its R&D activities without immediate pressure for additional financing, allowing focused investment in high-potential programs that could drive long-term earnings growth.

Want to see why this narrative supports such a high fair value gap to today’s price? The story leans heavily on rapid revenue expansion, shifting margins, and a very ambitious future earnings multiple. Curious which assumptions have the biggest impact on that $119.71 figure and how they tie back to pipeline milestones?

Result: Fair Value of $119.71 (UNDERVALUED)

However, this upside story still leans heavily on high R&D spend and partner execution, where trial setbacks or slower progress could quickly challenge today’s optimism.

Next Steps

Given the mix of excitement and caution here, now is a good time to look through the numbers yourself and decide where you stand. To help you weigh both sides of the story, start with the 2 key rewards and 4 important warning signs.

Ready for more investment ideas?

If Kymera has you thinking about what else could be worth your attention, this is the moment to line up a few more contenders before the next catalyst hits.

• Target potential value opportunities by scanning 53 high quality undervalued stocks that pair solid fundamentals with pricing that may not fully reflect their prospects.
• Strengthen your income focus by reviewing 13 dividend fortresses that aim to combine robust payouts with balance sheets that support ongoing distributions.
• Get ahead of the crowd by checking the screener containing 26 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.